

Consensus

SFE/SFHTA/AFCE consensus on primary aldosteronism, part 1: Epidemiology of PA, who should be screened for sporadic PA?

Consensus hyperaldostéronisme primaire SFE/SFHTA/AFCE, groupe 1 : épidémiologie de l'hyperaldostéronisme primaire (HAP), chez qui rechercher une forme sporadique d'HAP ?

Jean-Philippe Baguet^{a,*}, Olivier Steichen^b, Claire Mounier-Véhier^c, Philippe Gosse^d

^a Service de cardiologie, groupe hospitalier mutualiste, 38028 Grenoble, France

^b Service de médecine interne, hôpital Tenon, 75020 Paris, France

^c Service de médecine vasculaire et hypertension artérielle, centre hospitalier universitaire, 59037 Lille, France

^d Service de cardiologie/hypertension, CHU, 33075 Bordeaux, France

Abstract

Depending on the study, the prevalence of primary aldosteronism (PA) in patients with hypertension varies from 6 to 18%. Prevalence is higher in each of the following conditions, any one of which requires screening for PA: severe hypertension (systolic blood pressure [BP] ≥ 180 mmHg and/or diastolic BP ≥ 110 mmHg); resistant hypertension (systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg despite adherence to a tritherapy including a thiazide diuretic); hypertension associated with hypokalemia (either spontaneous or associated with a diuretic); Hypertension or hypokalemia associated with adrenal incidentaloma. It should be borne in mind that PA can induce hypertension without hypokalemia or, less frequently, hypokalemia without hypertension. Finally, as cardiovascular and renal morbidity in PA is greater than in essential hypertension of equivalent level, screening for PA is indicated when cardiovascular or renal morbidity is more severe than predicted from BP level.

© 2016 Elsevier Masson SAS. All rights reserved.

Keywords: Primary aldosteronism; Hypokalemia; Resistant hypertension; Severe hypertension; Adrenal incidentaloma; Cardiovascular morbidity

Résumé

Selon les études la prévalence de l'hyperaldostéronisme primaire (HAP) chez les patients hypertendus varie de 6 à 18 %. Cette prévalence est plus élevée dans chacune des conditions suivantes, qui justifient de rechercher systématiquement un HAP (une seule condition est suffisante) : hypertension artérielle (HTA) sévère (pression artérielle systolique [PAS] ≥ 180 mmHg ou pression artérielle diastolique [PAD] ≥ 110 mmHg) ; HTA résistante (PAS ≥ 140 mmHg et/ou PAD ≥ 90 mmHg malgré trithérapie comprenant un diurétique thiazidique) ; HTA associée à une hypokaliémie, qu'elle soit spontanée ou associée à la prise d'un diurétique ; HTA ou hypokaliémie associée à un incidentalome surrénalien. Il faut souligner qu'un HAP peut être responsable d'HTA sans hypokaliémie et, plus rarement, d'une hypokaliémie sans HTA. Par ailleurs, dans la mesure où la morbidité cardiovasculaire et rénale de l'HAP est plus élevée que celle observée dans une HTA de même niveau tensionnel, il apparaît justifié de rechercher un HAP lorsque le retentissement cardiovasculaire ou rénal de l'HTA apparaît disproportionné avec le niveau tensionnel.

© 2016 Elsevier Masson SAS. Tous droits réservés.

Mots clés : Hyperaldostéronisme primaire ; Hypokaliémie ; Hypertension résistante ; Hypertension sévère ; Incidentalome surrénalien ; Morbidité cardiovasculaire

1. Introduction

The exact prevalence of primary aldosteronism (PA) is unclear, as reports have differed in methodology and study population.

Several clinical presentations, principally including hypertension, are associated with a high risk of PA. At-risk patients to

* Corresponding author.

E-mail address: jp.baguet@ghm-grenoble.fr (J.-P. Baguet).

be screened for PA show one of the following: severe hypertension (grade 3), resistant hypertension, hypertension associated with hypokalemia, or associated with adrenal incidentaloma. In addition it is necessary to screen for a familial form of PA in specific situations which include young age and familial history of hypertension, stroke or PA, as described in the following article by Zennaro et al.

2. PA prevalence in hypertension

Several studies in recent years have improved knowledge of PA prevalence in hypertension.

Gordon et al. in 1994 reported 8.5–13% prevalence of PA in 199 patients with hypertension and normal kalemia, depending on whether diagnosis was founded on elevated aldosterone-renin ratio (ARR) on two measurements confirmed by fludrocortisone test, or on a single measurement without confirmation [1]. Other authors subsequently reported prevalence of 6.1–18% in tertiary care centers, depending on the study population and hormonal diagnosis procedure (with or without confirmation) [2–6]. In the light of these findings, the Endocrine Society estimated PA prevalence in hypertension at $\geq 10\%$ [7]. In 2012, Hanne-mann et al., in an epidemiological study of 2444 hypertensive patients in Germany, screening for PA by ARR elevation without confirmation test, reported prevalence of 7% [8].

There are two forms of PA, with differing prevalence in hypertension: idiopathic PA was more frequent (6.4%) than Conn's adenoma (4.8%) in the PAPY study [9].

The relation between hypertension and PA principally concerns the hypertensive action of aldosterone, as clearly shown in a large-scale epidemiological study based on the Framingham cohort [10]: in 1,688 subjects with normal blood pressure (BP), the risk of developing hypertension within a 4-year period was 14.8%, but this risk was multiplied by 1.61 in the upper quartile for aldosteronemia; ARR elevation, assayed in day-clinic in 3326 subjects with normal BP, was associated with a significant 1.16-fold extra risk (16%) of developing hypertension over a mean 3 years' follow-up [11].

3. PA detection in high-prevalence populations

R1.1: PA should be screened for in patients with severe hypertension (grade 3, systolic BP ≥ 180 mmHg and/or diastolic BP ≥ 110 mmHg) (Strong; evidence ++)

Prevalence of PA increases with the grade of hypertension, as demonstrated in several studies conducted in hypertension patients [3,8,9]. In the PAPY study, Rossi et al. reported 6.6% PA prevalence in grade-1 hypertension, 15.5% in grade 2 and 19% in grade 3 [9]. A similar correlation of PA prevalence (18.3%) with the severity of hypertension was found by Hannemann et al., screening for PA on ARR [8]. Conversely, PA was rare in

grade-1 hypertension, in which systematic PA screening would not be indicated, according to the Japan Endocrine Society [12].

4. Resistant hypertension

R1.2: PA should be screened for in patients with resistant hypertension ($\geq 140/90$ mmHg, despite adherence to lifestyle modifications and administration at optimal dose of ≥ 3 anti-hypertension drugs including 1 thiazide diuretic). (Strong; evidence ++)

Just as prevalence of PA increases with hypertension grade, prevalence is high in resistant hypertension: doubled on average, to around 20%, depending on the report. Douma et al. reported PA in 11.3% (on salt loading test) and 20.9% (on ARR and elevated aldosteronemia without confirmation test) of patients with resistant hypertension in a cohort of 1616 [13]. Calhoun et al. reported 30% prevalence, but defined PA in terms of urinary aldosterone and plasma renin activity [14]. More recently, a German epidemiological study reported lower prevalence, at 11.9% [8].

5. Hypertension with hypokalemia

R1.3: PA should be screened for in patients with hypertension associated with permanent or intermittent hypokalemia (< 3.5 mmol/l), whether spontaneous or diuretic-induced, without obvious digestive potassium loss. (Strong; evidence ++)

R1.4: Normal kalemia (≥ 3.5 to ≤ 5.0 mmol/l) in hypertension does not rule out PA, which should be screened for in case of normal kalemia associated with another indication for PA screening. (Strong; evidence ++)

Until the present decade, hypertension associated with hypokalemia (< 3.5 mmol/l) was a prerequisite for PA screening [15]. This attitude was challenged in the light of high PA prevalence without hypokalemia, whether spontaneous or induced by a potassium-reducing diuretic. Mulatero et al. showed that only a low proportion (9–37%, depending on the center) of PA patients were hypokalemic [16]. Similar proportions were also reported elsewhere [4,5,8].

Nevertheless, hypertensive patients with PA show lower kalemia. Seiler et al. reported mean kalemia of 3.74 mmol/l

in patients with PA, versus 4.37 mmol/l without [5]. Likewise, hypokalemia is more or less systematic in severe PA [9]. It should also be borne in mind that hypokalemia is more frequent in Conn's adenoma (48%) than in idiopathic PA (16.9%) [9].

6. Hypertension with adrenal incidentaloma

R1.5: PA should be screened for in patients with hypertension or hypokalemia associated with an adrenal lesion of ≥ 10 mm diameter revealed serendipitously (adrenal incidentaloma).

(Strong; evidence ++)

Adrenal incidentaloma is an adrenal lesion exceeding 10 mm, discovered serendipitously [17], in a patient without apparent signs of adrenal pathology, but possibly showing hypertension and/or hypokalemia.

PA prevalence in adrenal incidentaloma varies between reports: 1.6% in a retrospective study of 1,096 patients [18], 2% in a series operated on for incidentaloma [19], and $\geq 10\%$ in other series [20,21].

Vierhapper et al. found higher rates of PA in adrenal incidentaloma patients with hypertension (4%) than without ($< 1\%$) [22].

7. Morbidity-mortality in PA

R1.6-PA should be suspected in hypertensive patients in whom target organ damage or cardiovascular morbidity appear more severe than expected from the level and duration of hypertension.

(Weak; evidence +)

R1.7-Given the absence of therapeutic impact, indications for target organ lesions screening are the same in PA as in the general population of hypertensive patients.

(Weak; evidence +)

Aldosterone increases the risk of ischemic cardiopathy, heart failure and chronic kidney disease. This may be due to sodium and water retention, inflammation, endothelial dysfunction, cardiac, vascular or renal fibrosis, sympathetic potentialization, or insulin resistance. In PA, such effects, coming on top of hypertension and hypokalemia, increase cardiovascular and renal risk.

8. Cardiovascular impact

8.1. *Infraclinical impact*

8.1.1. *Left ventricle hypertrophy*

A recent systematic review of the literature and a large-scale cross-sectional comparative study updated the state of knowledge on the anatomic and functional impact of PA upon the left ventricle (LV) [23,24]. All studies show that PA increases LV telediastolic volume, variably associated with increased wall thickness, as compared to otherwise similar patients with essential hypertension.

These two phenomena combine in a prevalence odds ratio of about 2 for LV hypertrophy on echocardiography in PA patients versus patients with essential hypertension of the same BP level. Left ventricular hypertrophy regressed in all studies assessing specific medical or surgical PA treatment at sufficient follow-up.

Recent studies using tissue fibrosis markers in ultrasound or MRI confirmed increased myocardial fibrosis in the LV [25–29].

8.1.2. *Infraclinical atheroma*

Comparative studies between PA and essential hypertension reported signs of target organ damage that was excessive for the BP level and that resolved with specific treatment: endothelial dysfunction [30], increased pulse wave velocity [31], and higher carotid intima-media thickness [32,33].

8.2. *Clinical impact*

To date, five studies compared prevalence of cardiovascular events between patients with PA versus essential hypertension matched at least for BP [24,34–37].

In the most recent study, the prevalence odds ratio at PA diagnosis was 2.6 for myocardial infarction, 1.9 for symptomatic or revascularized ischemic cardiopathy, 2.9 for symptomatic heart failure, and 5.0 for atrial fibrillation [24]. The prevalence odds ratio of stroke was between 4 and 5 in those studies in which it was assessed [35,36].

Two of the studies went on to compare progression between PA and essential hypertension [36,37]: after specific medical or surgical treatment, the incidence of new cardiovascular events was identical between matched PA and essential hypertension patients in the first study [36]. The incidence of stroke and sustained arrhythmia remained higher in PA patients after specific treatment than in matched essential hypertension patients, but the difference was less than before [37].

9. Renal impact

Relative glomerular hyperfiltration is systematic at diagnosis of PA as compared to essential hypertension, according to a recent systematic review [38]. Specific medical or surgical treatment corrects this hyperfiltration and may reveal underlying chronic kidney failure, more frequently than in essential hypertension [39–42]. Microalbuminuria is also twice more frequent in PA than in essential hypertension of the same blood pressure

level [43], but tends to regress with specific medical or surgical treatment [39–41]; the impact of medical or surgical treatment of PA on microalbuminuria seems to be similar [44].

Disclosure of interest

The authors declare that they have no competing interest.

References

- [1] Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. *Clin Exp Pharmacol Physiol* 1994;21:315–8.
- [2] Lim PO, Dow E, Brennan G, Jung RT, MacDonald TM. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. *J Hum Hypertens* 2000;14:311–5.
- [3] Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, Montero J, et al. Primary aldosteronism and hypertensive disease. *Hypertension* 2003;42:161–5.
- [4] Stowasser M, Gordon RD, Gunasekera TG, Cowley DC, Ward G, Archibald C, et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. *J Hypertens* 2003;21:2149–57.
- [5] Seiler L, Rump LC, Schulte-Monting J, Slawik M, Borm K, Pavenstadt H, et al. Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication. *Eur J Endocrinol* 2004;150:329–37.
- [6] Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. *Clin Chem* 2005;51:386–94.
- [7] Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2008;93:3266–81.
- [8] Hannemann A, Bidlingmaier M, Friedrich N, Manolopoulou J, Spyroglou A, Volzke H, et al. Screening for primary aldosteronism in hypertensive subjects: results from two German epidemiological studies. *Eur J Endocrinol* 2012;167:7–15.
- [9] Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al. A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients. *J Am Coll Cardiol* 2006;48:2293–300.
- [10] Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. *N Engl J Med* 2004;351:33–41.
- [11] Newton-Cheh C, Guo CY, Gona P, Larson MG, Benjamin EJ, Wang TJ, et al. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. *Hypertension* 2007;49:846–56.
- [12] Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, Tamura N, et al. Guidelines for the diagnosis and treatment of primary aldosteronism—the Japan Endocrine Society 2009. *Endocr J* 2011;58:711–21.
- [13] Douma S, Petidis K, Doumas M, Papaefthymiou P, Triantafyllou A, Kartali N, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. *Lancet* 2008;371:1921–6.
- [14] Calhoun DA, Nishizaka MK, Zaman MA, Harding SM. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. *Chest* 2004;125:112–7.
- [15] Kaplan N. Clinical hypertension. 6th ed. Baltimore: Williams & Wilkins; 1994. p. 389–408.
- [16] Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. *J Clin Endocrinol Metab* 2004;89:1045–50.
- [17] Cawood TJ, Hunt PJ, O'Shea D, Cole D, Soule S. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? *Eur J Endocrinol* 2009;161:513–27.
- [18] Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. *J Clin Endocrinol Metab* 2000;85:637–44.
- [19] Bulow B, Ahren B. Adrenal incidentaloma—experience of a standardized diagnostic programme in the Swedish prospective study. *J Intern Med* 2002;252:239–46.
- [20] Kim HY, Kim SG, Lee KW, Seo JA, Kim NH, Choi KM, et al. Clinical study of adrenal incidentaloma in Korea. *Korean J Intern Med* 2005;20:303–9.
- [21] Unger N, Lopez Schmidt I, Pitt C, Walz MK, Philipp T, Mann K, et al. Comparison of active renin concentration and plasma renin activity for the diagnosis of primary hyperaldosteronism in patients with an adrenal mass. *Eur J Endocrinol* 2004;150:517–23.
- [22] Vierhapper H. Determination of the aldosterone/renin ratio in 269 patients with adrenal incidentaloma. *Exp Clin Endocrinol Diabetes* 2007;115:518–21.
- [23] Milan A, Magnino C, Fabbri A, Chiarlo M, Bruno G, Losano I, et al. Left heart morphology and function in primary aldosteronism. *High Blood Press Cardiovasc Prev* 2012;19:11–7.
- [24] Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. *Hypertension* 2013;62:331–6.
- [25] Rossi GP, Di Bello V, Ganzaroli C, Sacchetto A, Cesari M, Bertini A, et al. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. *Hypertension* 2002;40:23–7.
- [26] Lee HH, Hung CS, Wu XM, Wu VC, Liu KL, Wang SM, et al. Myocardial ultrasound tissue characterization of patients with primary aldosteronism. *Ultrasound Med Biol* 2013;39:54–61.
- [27] Lin YH, Lee HH, Liu KL, Lee JK, Shih SR, Chueh SC, et al. Reversal of myocardial fibrosis in patients with unilateral hyperaldosteronism receiving adrenalectomy. *Surgery* 2011;150:526–33.
- [28] Lin YH, Wu XM, Lee HH, Lee JK, Liu YC, Chang HW, et al. Adrenalectomy reverses myocardial fibrosis in patients with primary aldosteronism. *J Hypertens* 2012;30:1606–13.
- [29] Freel EM, Mark PB, Weir RA, McQuarrie EP, Allan K, Dargie HJ, et al. Demonstration of blood pressure-independent noninfarct myocardial fibrosis in primary aldosteronism: a cardiac magnetic resonance imaging study. *Circulation* 2012;125:740–7.
- [30] Tsuchiya K, Yoshimoto T, Hirata Y. Endothelial dysfunction is related to aldosterone excess and raised blood pressure. *Endocr J* 2009;56:553–9.
- [31] Strauch B, Petrak O, Zelinka T, Wichterle D, Holaj R, Kasalicky M, et al. Adrenalectomy improves arterial stiffness in primary aldosteronism. *Am J Hypertens* 2008;21:1086–92.
- [32] Lin YH, Lin LY, Chen A, Wu XM, Lee JK, Su TC, et al. Adrenalectomy improves increased carotid intima-media thickness and arterial stiffness in patients with aldosterone producing adenoma. *Atherosclerosis* 2012;221:154–9.
- [33] Holaj R, Rosa J, Zelinka T, Strauch B, Petrak O, Indra T, et al. Long-term effect of specific treatment of primary aldosteronism on carotid intima-media thickness. *J Hypertens* 2015;33:874–82.
- [34] Takeda R, Matsubara T, Miyamori I, Hatakeyama H, Morise T. Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan. *J Endocrinol Invest* 1995;18:370–3.
- [35] Milliez P, Gierard X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. *J Am Coll Cardiol* 2005;45:1243–8.
- [36] Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. *Arch Intern Med* 2008;168:80–5.
- [37] Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, Iannaccone A, et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. *J Clin Endocrinol Metab* 2013;98:4826–33.
- [38] Kuo CC, Wu VC, Tsai CW, Wu KD. Relative kidney hyperfiltration in primary aldosteronism: a meta-analysis. *J Renin Angiotensin Aldosterone Syst* 2011;12:113–22.

- [39] Ribstein J, Du Cailar G, Fesler P, Mimran A. Relative glomerular hyperfiltration in primary aldosteronism. *J Am Soc Nephrol* 2005;16:1320–5.
- [40] Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL, et al. Long-term renal outcomes in patients with primary aldosteronism. *JAMA* 2006;295:2638–45.
- [41] Wu VC, Kuo CC, Wang SM, Liu KL, Huang KH, Lin YH, et al. Primary aldosteronism: changes in cystatin C-based kidney filtration, proteinuria, and renal duplex indices with treatment. *J Hypertens* 2011;29:1778–86.
- [42] Utsumi T, Kawamura K, Imamoto T, Nagano H, Tanaka T, Kamiya N, et al. Preoperative masked renal damage in Japanese patients with primary aldosteronism: identification of predictors for chronic kidney disease manifested after adrenalectomy. *Int J Urol* 2012;20:685–91.
- [43] Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, et al. Renal damage in primary aldosteronism: results of the PAPY Study. *Hypertension* 2006;48:232–8.
- [44] Fourkoti V, Vonend O, Diederich S, Fischer E, Lang K, Endres S, et al. Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism. *Eur J Endocrinol* 2013;168:75–81.